Helsinki, Finland 16 May – the Finnish biotech company Mobidiag announced today the Prove-it™ Bone and Joint microarray assay for the identification of bacteria responsible for bone and joint infections (BJIs). The microbiological diagnostics of BJIs currently relies on cultures, which are time consuming and subject to false negative results in case of fastidious organisms and previous antibiotic therapy. Mobidiag’s Prove-it™ Bone and Joint identifies bacteria directly from a clinical sample in only three hours and enables rapid implementation of targeted antimicrobial treatment. The product adds new capabilities to Mobidiag’s microarray platform, which also covers sepsis causing bacteria. It can now detect a world record of 64 dangerous bacteria in a single test.

Read the whole Press Release here.